RAB37 ORCHESTRATES THE SREBP/SCD AXIS TO MODULATE LIPID METABOLISM AND DRIVE FERROPTOSIS RESISTANCE IN ACUTE MYELOID LEUKEMIA (EHA 2025) - May 16, 2025 - Abstract #PS1442; Pres time: Jun 14, 2025; 06:30 PM - 07:30 PM; Location: Poster Hall; "Ferroptosis sensitivity was evaluated using ferroptosis inducers ( erastin) and genetic/pharmacological inhibition of RAB37 and SCD... Our findings reveal a novel RAB37-mediated regulatory mechanism linking fatty acid anabolic pathways to ferroptosis resistance in AML. By orchestrating the SREBP/SCD axis, RAB37 drives MUFA synthesis and lipid droplet formation, conferring resistance to ferroptosis and contributing to AML progression and therapy resistance. These results highlight the potential of RAB37 and the SREBP/SCD axis as prognostic biomarkers and therapeutic targets."
Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Metabolic Disorders • Oncology
|